Printer Friendly

DARA BioSciences wins stockholder's approval of merger with and into Midatech.

M2 EQUITYBITES-December 3, 2015-DARA BioSciences wins stockholder's approval of merger with and into Midatech


DARA BioSciences (NasdaqCM:DARA) reported on Wednesday the receipt of stockholders' approval for the adoption of the merger agreement by and among DARA, Midatech Pharma PLC (Midatech) and certain other parties thereto.

Following completion of the planned merger agreement, DARA will become a wholly owned subsidiary of Midatech.

The merger remains subject to customary closing conditions and is expected to close in the next week.

Located in Raleigh, North Carolina, DARA BioSciences Inc is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments. DARA holds exclusive US marketing rights to Gelclair oral rinse gel, Oravig (miconazole) buccal tablets and Soltamox (tamoxifen citrate oral liquid solution).

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 3, 2015
Previous Article:RAI's board approves 46th consecutive quarterly cash dividend of USD0.36 per share for quarter.
Next Article:Holmen announces restart of paper machine PM 12 at Hallsta Paper Mill.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters